![](/wp-content/uploads/2020/06/welldoc-fractyl-announcement.png)
$599
Welldoc Insulin Adjustment Program Approved by FDA; Fractyl to Initiate Study for Insulin-dependent T2DM Patients
Two diabetes-related news items have been observed: Welldoc announced FDA approval of an additional feature for the BlueStar platform called the Insulin Adjustment Program (IAP) and Fractyl Laboratories announced FDA approval of an Investigational Device Exemption (IDE) to initiate a study examining the effects of Revita DMR in T2DM patients treated with insulin. Below FENIX provides highlights and insights for the respective news items.